首页 › 基金 › Catalio Capital Management, LP › BBOT
Catalio Capital Management, LP 对 BBOT 的持仓历史
BRIDGEBIO ONCOLOGY THERAPEUT · 医疗保健
Catalio Capital Management, LP 在 Q3 2026 的 13F 申报中披露持有 BBOT(BRIDGEBIO ONCOLOGY THERAPEUT)699,532 股,市值约 US$2.9M,约占其申报组合的 0.54%,在其申报持仓中市值排名第 38 位。 Catalio Capital Management, LP 最近 2 个申报季度中有 2 个季度披露了 BBOT 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Catalio Capital Management, LP 对 BBOT 的持仓演变
Catalio Capital Management, LP 于 Q2 2026 首次披露 BBOT 持仓:318,407 股(约 US$2.4M)。 该持仓在 Q3 2026 达到峰值 699,532 股,市值约 US$2.9M。 在 2 次申报中,Catalio Capital Management, LP 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 699,532 股、市值约 US$2.9M,环比增持 381,125 股。。 持仓曾出现大幅变动:Q3 2026 增持约 120% (随后一个季度股价下跌 52%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 318.41K | $2.43M | 新进 |
| Q3 2026 | 699.53K | $2.87M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BBOT 与 13F 数据
BBOT(BRIDGEBIO ONCOLOGY THERAPEUT)属于医疗保健行业。我们追踪的基金中还有 87 只申报持有 BBOT,申报仓位最大的包括:Cormorant Asset Management, LP (US$73.3M), Omega Fund Management, LLC (US$13.5M), Alphabet Inc. (US$11.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 BBOT 的基金
- Cormorant Asset Management, LP 17.88M 股 · $73.30M · Q3 2026
- Omega Fund Management, LLC 3.29M 股 · $13.49M · Q3 2026
- Alphabet Inc. 2.82M 股 · $11.57M · Q3 2026
- Enavate Sciences GP, LLC 2.63M 股 · $10.77M · Q3 2026
- REGENTS OF THE UNIVERSITY OF CALIFORNIA 2.51M 股 · $10.29M · Q3 2026
- Novo Holdings A/S 2.25M 股 · $9.22M · Q3 2026
- Opaleye Management Inc. 700.00K 股 · $5.33M · Q2 2026
- Aisling Capital Management LP 1.02M 股 · $4.14M · Q3 2026
- EcoR1 Capital, LLC 889.61K 股 · $3.65M · Q3 2026
- Casdin 资本 282.31K 股 · $1.16M · Q3 2026
更多关于 Catalio Capital Management, LP
常见问题
How long has Catalio Capital Management, LP held BBOT?
Catalio Capital Management, LP has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Catalio Capital Management, LP's current position in BBOT?
As of Q3 2026, Catalio Capital Management, LP holds 699.53K shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), valued at $2.87M, representing 0.54% of its reported portfolio and ranking #38.
Has Catalio Capital Management, LP been buying or selling BBOT?
In the latest 13F filing (Q3 2026), Catalio Capital Management, LP increased its position in BBOT. The position peaked in Q3 2026 at 699.53K shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, Omega Fund Management, LLC, Alphabet Inc., among 87 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.